TAGline November 2022
This year’s edition of TAGline commemorates TAG’s 30th anniversary, and these articles explore TAG’s work over the years: what we've accomplished, what we've learned, the continuing obstacles to progress, and what comes next.
Introducing 1/4/6×24: A Campaign That Draws Inspiration from the Past to Change the Trajectory of the Future Fight to End Tuberculosis
By Lindsay McKenna, Mike Frick, and Mark Harrington At the 24th International AIDS Conference in Montreal this summer, TAG, Partners In Health (PIH), and Médecins Sans Frontières (MSF) launched the 1/4/6x24 Campaign to accelerate equitable global uptake of newly discovered…
Community Representation in HIV Research: From Study Volunteers to Investigators
By Cheriko A. Boone, Abraham Johnson, and Richard Jefferys In a 1989 article by Dr. Anthony Fauci, “AIDS — Challenges to Basic and Clinical Biomedical Research” — which preceded Treatment Action Group’s founding by just a few years — he…
Political Neglect and Corporate Greed: A Panel Discussion on Finding and Treating the #MissingMillions with TB + HCV
By David Branigan, Joelle Dountio Ofimboudem, and Natalie Shure TAG was founded in 1992 with the aim of accelerating the availability of effective HIV treatments through science-based advocacy at every step of the research, development, and implementation process. These strategies…
TAG at 30: Milestones
By Dorrit Walsh and Mark Harrington Since 1992, Treatment Action Group has been advocating for those affected by and struggling with HIV. Since then, we’ve expanded our mission to include tuberculosis (TB) — the leading cause of death by infectious…
Towards Pandemic Equity: Lessons from 30 Years of Syndemic Activism
By Mike Frick and Mark Harrington The articles in this 30th anniversary issue of TAGline grapple with “pandemic equity,” an increasingly common catchphrase in global health. COVID-19 has shown that “equity,” like its cousins “justice,” “fairness,” and “equality,” is one…
TAGline October 2021
Delivering on the Promise of Long-Acting Forumulations delves deep into the development of long-acting formulations for the treatment and prevention of infectious diseases like HIV, tuberculosis, hepatitis C, and malaria. Long-acting medications have become common for conditions such as osteoporosis and schizophrenia, and they're even used for birth control.
Long-Acting Therapy for Malaria Prevention: Toward a Malaria-Free World
By Joelle Dountio Ofimboudem Malaria is a life-threatening disease prevalent in the world’s poorest countries, particularly in sub-Saharan Africa. Preventing malaria hits close to home for me. I am a mother to two children, aged three and five. We are…
Developing Long-Acting Cures to Accelerate the End of Hepatitis C: Interview with Dr. Dave Thomas
Interview questions and editing by Erica Lessem, Bryn Gay, Joelle Dountio Ofimboudem, Annette Gaudino, and Elizabeth Lovinger The World Health Organization set ambitious targets for eliminating the hepatitis C virus (HCV) among the 58 million people living with the disease,…
Injectables Redux: Developing Acceptable Long-Acting Formulations for TB Prevention Amidst a Push for All-Oral Treatment
By David Branigan Ensuring access to tuberculosis (TB) preventive treatment for people most at risk of developing active TB is one of the key interventions required to end TB.1 Central to these efforts is the push to scale up short…